

# 2017 Consumer Calendar **ORDERS NOW OPEN!**

Health can be an adventure

Exclusive to Symbion Account holders

Call 1800 036 367 or place your order

### Today's issue of PD

Pharmacy Daily today has two pages of news, plus a full page featuring the MIMS July update.

# Chlorofluor recall

**THE** Therapeutic Goods Administration has announced the recall of a batch of Chlorofluor Gel due to bacterial contamination.

The product is being recalled by Professional Dentist Supplies, after testing of unopened bottles from batch BK 119 detected high levels of Burkholderia cepacia.

The affected batch has been associated with two cases of B. cepacia infection at the Royal Adelaide Hospital, where the batch has already been removed.

Chlorofluor Gel is an oral hygiene product containing 2mg/ ml of chlorhexidine, and can be purchased over the counter.

According to the TGA B. cepacia poses little medical risk to healthy people, but could prove problematic for people with weakened immune systems.

Effects vary widely and range from no symptoms at all through to serious respiratory infections, especially in patients with chronic lung diseases such as cystic fibrosis.

# Health destination sensation THE Pharmaceutical Society of Australia says its new "Health

Destination Pharmacy" program (PD 03 Aug 2015) has seen participating pharmacies achieve a 6.4% increase in average sale just six months after it was launched.

That's well above the industry average increase of 1.8% since Oct last year, according to a new independent analysis commissioned by the PSA.

"The evidence-based Health Destination Pharmacy program has successfully repositioned pharmacists as local healthcare providers and empowered pharmacies to provide high quality consumer healthcare in their local communities," the PSA said in a statement issued today.

PSA's executive director of Policy, Advocacy and Innovation, Alison Roberts, said the results of the study highlight that pharmacies investing in the Health Destination Pharmacy solution are delivering more customer-focused care.

"These results reinforce that the program works, however we don't always expect to see success so quickly - it's a credit to the pharmacists and their teams working hard on change and being

# Worried about membership costs and PBS reform?

Improve the health of your pharmacy with SmarterPharm

- Excellent PBS and OTC wholesale trading terms
- Negotiated generic supplier deals
- OTC buying guide
- Vaccine supply deal
- Professional Services Support Program
- Retail Management Solutions

www.smarterpharm.com.au office@smarterpharm.com.au P: 0438 402 713 or 0466 711 702



supported by our expert coaches through this program," she said.

Roberts added that pharmacists participating in the program were reporting positive feedback across the board, including from GPs, consumers and local healthcare organisations - and in turn the Health Destination pharmacies were seeing improvements in their business viability.

PSA national president Joe Demarte said the results of the analysis speak for themselves, with the Health Destination program, led by industry experts in pharmacy change, achieving its aims of "supporting pharmacies to build a viable, value-adding business platform to ensure their future sustainability".

### The Mayne game

MAYNE Pharma's proposed \$800-million plus US acquisition of a portfolio of generics (PD 28 Jun) could see the company catapulted into the top 100 publicly listed companies in Australia.

The move is likely to attract increased institutional investment. according to Fairfax Media, with the deal seeing Mayne's share price surge almost 29% last week, while the equity raising to fund the deal likely to lift its capitalisation to as much as \$3 billion.

The 42 generics being acquired from Teva and Allergan have an average profit margin around 50% which is more than twice Mayne's current margin levels and also opens the company up to new markets such as oral contraceptives.

Analysts are reported to say that the higher margins will raise cash flow and go towards eliminating most of the group's debt over the next 18 months or so.

## WeChat to Roy Young

CHATSWOOD, Sydney-based pharmacy Roy Young Chemist, part of the Pharmacy 4 Less chain, has made effective inroads into the Chinese online OTC pharma market via the WeChat App, China's answer to Facebook, Instagram and Tinder, reports Fairfax Media.

With now more than 10,000 followers in China, Rania Awad, the pharmacy's e-commerce manager says, "We're able to interact directly with our customers and it increases the trust."



# 2016 **Blackmores** Institute **Symposium**

Integrating complementary medicine into pharmacy practice



### 13 August, 2016 Sheraton on the Park, Sydney

Full program available at:

NEW

complimentary training for

**Pharmacy** 

Assistants

pharmacy Club



### For effective temporary soothing relief of coughs & chesty congestion from colds W

Helps break down mucus and clear the chest Contains natural ivy leaf extract Suitable for children 6 months\*

your healthcare professional before using in children under 2 years. Always read the label. Use only as directed, if sy



### **MSD** pushes parents

FOLLOWING a recent CDC recommendation that 11 and 12 year olds be vaccinated against human papilloma virus (HPV), MSD has released a controversial video ad putting the onus on parents to take the initiative with its Gardasil.

In the American TV ad, a young adult male with cancer caused by HPV is shown in a series of pictures traversing back in time as he wonders whether his parents just didn't know about the vaccine that could have protected him.

MSD said the campaign was necessary because research revealed while 85% of parents know about HPV, only about 50% were aware of the carcinogenicity link.

### CLICK HERE for the advert video.

### **Brexit to NHSexit**

**BRITAIN'S** exit from the European Union could have unintended consequences for the UK's National Health Service, reports the BBC.

Eight percent, or 10,000 of the physicians and more than 18,000 of nurses practicing in the NHS are originally from European countries. Brexit could mean recruitment

of health professionals may prove difficult, at a time when there is already a significant exodus of staff.

# SHPA names gm advocacy

#### THE Society of Hospital

Pharmacists of Australia has today announced the appointment of Johanna de Wever as its new General Manager of Advocacy and Leadership.

SHPA ceo Kristin Michaels said de Wever would be a "key member of our new management team as we create a vision for the future of the profession and advocate for changes that will deliver better medicines management and more rewarding career paths".

De Wever, who has qualifications in media, communications and e-marketing, began her career in

### **Blackmores running** festival bookings

**BLACKMORES** is once again the major sponsor of the Sydney Running Festival this year, with earlybird registration now available offering savings of up to \$20.

The course this year is "flatter, faster and even more beautiful" and there is a range of distances on offer including the 4km Family Fun Run which returns to the Sydney Opera House.

The event takes place 18 Sep - for more details CLICK HERE.

### WITH CARMEX WIN

This week Pharmacy Daily and Carmex are giving readers the chance to win a Carmex prize pack including a Click Stick, Jar, Tube, Moisture Plus in Sheer and Jasmine Green Tea, valued at \$31.95.

Carmex lip balms are an Australian favourite and are an essential part of any beauty routine. The range features SPF15 plus cooling and soothing properties that lips crave. Visit FACEBOOK for more information.



To win, be the first from NSW or ACT to send the correct answer to the following question to comp@pharmacydaily.com.au

What are the Carmex colours?

Check here tomorrow for today's winner.

Pharmacy Daily is Australia's favourite pharmacy industry publication. Sign up free at www.pharmacydaily.com.au.

Postal address: PO Box 1010, Epping, NSW 1710 Australia Street address: Suite 1, Level 2, 64 Talavera Rd, Macquarie Park NSW 2113 Australia P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)

#### Part of the Business Publishing Group,

trave Bulletin business events news



Publisher: Bruce Piper info@pharmacydaily.com.au

Reporter: Mal Smith Contributors: Nathalie Craig, Jasmine O'Donoghue, Bonnie Tai Advertising and Marketing: Magda Herdzik, Sean Harrigan, Melanie Tchakmadjian advertising@pharmacydaily.com.au Business Manager: Jenny Pi

accounts@pharmacydaily.com.au CRUISE



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

Travel Daily



professionals

pharmacist (Jub

pharmacistclub.com.au

35,000 engaged pharmacy

pharmacy Club

pharmacyclub.com.au

advertising, before moving into

the health and welfare sector in

Foundation where she developed

reduction in alcohol-related harm.

work on dental funding with the

Brotherhood of St Laurence as well

as with the Royal Australian & NZ

College of Psychiatrists where she

The appointment is the latest

move in the national restructure

seen the appointment of Sally

of the organisation which has also

Ridgers as SHPA's General Manager

of Education and Services (PD 25

May) and Andrew Matthews as

General Manager of Workforce

Michaels said the restructuring

was seeing SHPA allocate resources

Transformation (PD 23 May).

to offer a more robust value

state government decisions.

**EXPORT** of therapeutic

goods by pharmacists, abuse of

diphenhydramine and a report on

errors involving methotrexate are

just a few of the issues addressed

in the June Circular (# 7) from the

Victorian Pharmacy Authority.

Methotrexate errors have

occurred in the packing of dose

administration aids resulting in

overdose (PD 07 Jun) prompting

the VPA to recommend a series of

preventative measures be in place.

Schedule 8 poisons procedures

are again in the spotlight with

a number of misdemeanours

recorded in the Panel Hearings.

Pharmacists are encouraged

to implement regular self-audit

compliance, for which purpose the

Authority has posted a self-audit

More at pharmacy.vic.gov.au.

procedures to ensure ongoing

form on its website HERE.

proposition to its members, and

seek to influence key federal and

VPA recaps reminders

managed their premature mortality

2003 with the Australian Drug

resources and advocated for

Other roles have included

campaign.

PROVOKED by pesky paparazzi? We have the answer for you, your very own flash photo invisibility cloak, or at least, scarf.

The ISHU scarf is the brainchild of Dutch-born fashion entrepreneur Saif Siddiqui and is designed to 'give people their right to privacy back', according to a report in *The Telegraph*.

It looks like an ordinary scarf, but works by reflecting back a flash of light blackening the rest of the photograph.

Join celebrities including Paris Hilton (pictured), Cameron Diaz, singer Joe Jonas, Bayern Munich footballer Jerome Boateng and music producer Major Lazer in anonymity by choice



CANNABIS 'ATMs' may soon become one of the first sights tourists see on arrival in Jamaica.

The drug was decriminalised in the island nation last year, making it legal to carry two ounces. Now The Cannabis Licensing Authority (CLA) wants Jamaica's air and seaports to set up dedicated kiosks where visitors can pick up a licence to sample some of the 'good herb' to help them chill out during their stay.

The CLA believes such a system would represent a "significant revenue stream for the Government".

There would still be some regulation with the kiosks to be staffed by people with medical training who will only permit the use of two ounces of the herb. Bob Marley would approve.

# MIMS

# Monthly Update

# **New Products**

Praxbind (idarucizumab, rch) is a humanised monoclonal antibody fragment (Fab) molecule derived from murine IgG1 isotype antibody molecule. It binds to dabigatran with very high affinity, approximately 300-fold higher than the binding affinity of dabigatran for thrombin at physiological pH (pH 7.4). Idarucizumab specifically binds to dabigatran and its acyl glucuronide metabolites and potently neutralises their anticoagulant effect. Idarucizumab is a specific reversal agent for dabigatran. Praxbind is indicated in patients treated with dabigatran etexilate (Pradaxa) when rapid reversal of the anticoagulant effects of dabigatran is required for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding. Praxbind is available as a 50 mg/mL solution for injection/infusion in a 50 ml glass vial in packs of 2's.

### Signifor LAR (pasireotide

(embonate)) is a cyclohexapeptide, injectable somatostatin analogue. Like natural peptide hormones somatostatin-14 and somatostatin-28 (also known as somatotropin release inhibiting factor (SRIF)) and other somatostatin analogues, pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). Pasireotide binds with high affinity to four of the five SSTRs. Signifor LAR is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues. Signifor LAR is contraindicated in severe hepatic impairment (Child Pugh C). Signifor LAR is available as 20 mg, 40 mg and 60 mg powder for injection vial in packs of 1's (also with one prefilled syringe containing diluent, one vial adaptor and one safety injection).

### Xofigo (radium (223Ra)

dichloride) is a therapeutic alpha particle emitting pharmaceutical with targeted anti-tumour effect on bone metastases. The active moiety of Xofigo is the isotope Ra-223 (as Ra-223 dichloride), which mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters (80 keV/micrometre) leads to a high frequency of double strand DNA breaks in adjacent cells, resulting in a potent and localised anti-tumour effect. Xofigo is indicated for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. Xofigo is available as a ready to use solution for injection in a 6 mL vial (corresponding to a total activity of 6.6 MBq per vial) in packs of 1's.

# July 2016

# Safety Related Changes

Skelid (tiludronate disodium) should not be used in juvenile

Pagetic patients as safety and efficacy has not been established.

Valoid (cyclizine lactate) should not be given to patients who have acute myocardial infarction. Valoid

should also not be given to patients who have acute alcohol intoxication. The anti-emetic properties of cyclizine may increase the toxicity of alcohol.

Voltaren (diclofenac sodium) is now contraindicated in patients with severe hepatic impairment. Voltaren is now also contraindicated in the treatment of perioperative pain in setting of coronary artery bypass surgery (CABG).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.